Literature DB >> 8043461

Subependymal giant cell astrocytomas in children.

G Sinson1, L N Sutton, A T Yachnis, A C Duhaime, L Schut.   

Abstract

Between 1977 and 1991, at the Children's Hospital of Philadelphia, 10 patients, 5-16 years of age, were diagnosed as having subependymal giant cell astrocytomas. These patients accounted for 1.4% of all pediatric brain tumors seen during that time interval. One patient received a course of radiation therapy, which was ineffective in preventing tumor growth. All underwent surgical resections with the goal being maximal tumor debulking, if not complete resection. In 6 patients this was accomplished by the frontal transventricular route and, in the more recent patients, surgery was performed using a transcallosal approach. There were 2 perioperative deaths, and 2 other patients died later of causes unrelated to tumor progression. The remaining 6 patients remain alive and stable at a mean of 6.7 years of follow-up (range 1.8-12.4). None of these patients has received additional radiation therapy. Two patients have no other evidence of tuberous sclerosis. The use of modern radiographic and surgical techniques has made the treatment of this disease safer than in the past.

Entities:  

Mesh:

Year:  1994        PMID: 8043461     DOI: 10.1159/000120796

Source DB:  PubMed          Journal:  Pediatr Neurosurg        ISSN: 1016-2291            Impact factor:   1.162


  17 in total

1.  Neurosurgical treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex: a series of 44 surgical procedures in 31 patients.

Authors:  Flavio Giordano; Carla Moscheo; Matteo Lenge; Roberto Biagiotti; Francesco Mari; Iacopo Sardi; Anna Maria Buccoliero; Lorenzo Mongardi; Eleonora Aronica; Renzo Guerrini; Lorenzo Genitori
Journal:  Childs Nerv Syst       Date:  2019-12-18       Impact factor: 1.475

2.  The diagnosis and treatment of subependymal giant cell astrocytoma combined with tuberous sclerosis.

Authors:  Tao Jiang; Ge Jia; ZhenYu Ma; ShiQi Luo; YuQi Zhang
Journal:  Childs Nerv Syst       Date:  2010-04-27       Impact factor: 1.475

3.  Biological behavior and tumorigenesis of subependymal giant cell astrocytomas.

Authors:  S K Kim; K C Wang; B K Cho; H W Jung; Y J Lee; Y S Chung; J Y Lee; S H Park; Y M Kim; G Choe; J G Chi
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

Review 4.  Management of subependymal giant cell tumors in tuberous sclerosis complex: the neurosurgeon's perspective.

Authors:  Moncef Berhouma
Journal:  World J Pediatr       Date:  2010-05-21       Impact factor: 2.764

Review 5.  The management of subependymal giant cell tumors in tuberous sclerosis: a clinician's perspective.

Authors:  Romina Moavero; Mariangela Pinci; Roberta Bombardieri; Paolo Curatolo
Journal:  Childs Nerv Syst       Date:  2011-02-09       Impact factor: 1.475

Review 6.  Subependymal giant cell astrocytoma: current concepts, management, and future directions.

Authors:  Taohui Ouyang; Na Zhang; Thomas Benjamin; Long Wang; Jiantong Jiao; Yiqing Zhao; Jian Chen
Journal:  Childs Nerv Syst       Date:  2014-02-19       Impact factor: 1.475

7.  Surgery for subependymal giant cell astrocytomas in children with tuberous sclerosis complex.

Authors:  Martine Fohlen; Sarah Ferrand-Sorbets; Olivier Delalande; Georg Dorfmüller
Journal:  Childs Nerv Syst       Date:  2018-05-15       Impact factor: 1.475

8.  Resection of subependymal giant cell astrocytoma guided by intraoperative magnetic resonance imaging and neuronavigation.

Authors:  Hecheng Ren; Xiaolei Chen; Guochen Sun; Shen Hu; Gang Zheng; Fangye Li; Jinjiang Li; Bainan Xu
Journal:  Childs Nerv Syst       Date:  2013-02-10       Impact factor: 1.475

9.  Subependymal giant cell astrocytoma: a report of five cases.

Authors:  Raj Kumar; Vinita Singh
Journal:  Neurosurg Rev       Date:  2004-08-12       Impact factor: 3.042

10.  Current trends in the management of subependymal giant cell astrocytomas in tuberous sclerosis.

Authors:  Paolo Frassanito; Carolina Noya; Gianpiero Tamburrini
Journal:  Childs Nerv Syst       Date:  2020-09-25       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.